ARCHIVED - 8.0 Vaccines

Currently, there are no vaccines approved for use in Canada for the prevention of GAS infections. There are a number of vaccines under development. Recent results of a phase I trial of a multivalent vaccine in the United States have demonstrated significant increases in antibody levels to all six component M antigens used in the vaccine among healthy adult volunteers⁽⁷⁷⁾. Results of a phase I trial and preliminary results of a phase II trial for a multivalent vaccine in Canada have also shown high titres of antibodies to 26 targeted serotypes contained in the vaccine among healthy adult volunteers^(78,79).There was no evidence of tissue cross-reactive antibodies or vaccine-related serious adverse events among participants for either vaccine.